KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1537.00
-¥23.00(-1.53%)
At close: 4:00 PM EST
¥1537.00
-¥23.00(-1.53%)
Day’s Range― - ―
52-Week Range¥1,359.00 - ¥1,725.00
Previous CloseN/A
Volume61.80K
Average Volume (3M)127.03K
Market Cap
¥84.49B
Enterprise Value¥105.84B
Total Cash (Recent Filing)¥16.62B
Total Debt (Recent Filing)¥26.48B
Price to Earnings (P/E)8.4
Beta0.54
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)45.70
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)0.66
P/FCF Ratio-39.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)81.05
Revenue Forecast (FY)¥126.47B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent mid-single-digit to high-single-digit revenue expansion (8.83% YoY) signals sustained end-market demand and effective commercialization in KYORIN's respiratory, infectious disease and immunology franchises. Over a 2–6 month horizon this supports predictable top-line momentum, funds ongoing R&D and lifecycle investments, and strengthens negotiating leverage with wholesalers and payers for stable future revenues.
Margin SustainabilityA structurally strong gross margin (45.75%) indicates durable product-level profitability and disciplined manufacturing/COGS controls. This margin cushion helps absorb raw-material or pricing pressure, enables continued SG&A and R&D investment without immediate margin erosion, and supports medium-term operating leverage as sales scale.
Balance Sheet StrengthHigh equity ratio (70.39%) and low debt-to-equity (0.21) reflect conservative leverage and financial flexibility. This structural strength reduces refinancing risk, preserves borrowing capacity for clinical programs or launches, and allows the company to weather reimbursement shifts or one-off costs without immediate strain on operations over the coming months.
Bears Say
Cash GenerationPersistent negative free cash flow and a low operating-cash-to-income ratio (0.39) show earnings are not converting efficiently to cash. Over a 2–6 month timeframe this constrains the company's ability to self-fund capex, R&D or launches, may force reliance on external financing or asset sales, and limits strategic flexibility in prioritizing investments.
Liquidity RiskA declining cash balance, noted despite low leverage, reduces financial buffers for product launches, clinical spending or unexpected NHI pricing changes. Shrinking cash reserves heighten the chance of near-term funding constraints, potentially necessitating urgent financing or delaying strategic initiatives within the next several months.
Operational Margin VolatilityReported swings in EBIT and EBITDA margins point to inconsistent operational performance tied to product mix, cost variability or episodic items. Margin volatility undermines earnings predictability, complicates multi-quarter planning and could impair the company's ability to reliably fund R&D or commercialization activities over the medium term.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1359.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥84.49B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is May 12, 2026 which is in 19 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on Feb 04, 2026. The company reported ¥45.7 earnings per share for the quarter, beating the consensus estimate of N/A by ¥45.7.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥37 which represents an annual dividend yield of 3.36%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of ¥45.7 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.672%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---